Three Seasons Wealth LLC Makes New $1.17 Million Investment in Zoetis Inc. (NYSE:ZTS)

Three Seasons Wealth LLC acquired a new position in Zoetis Inc. (NYSE:ZTS - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 7,177 shares of the company's stock, valued at approximately $1,169,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC raised its position in shares of Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after acquiring an additional 140 shares during the last quarter. Rakuten Securities Inc. grew its position in shares of Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after buying an additional 166 shares during the period. Murphy & Mullick Capital Management Corp bought a new stake in shares of Zoetis in the 4th quarter valued at about $44,000. Asset Planning Inc acquired a new stake in shares of Zoetis in the 4th quarter valued at approximately $58,000. Finally, Pilgrim Partners Asia Pte Ltd bought a new position in Zoetis during the 4th quarter worth approximately $59,000. 92.80% of the stock is owned by institutional investors.

Insider Activity at Zoetis

In related news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares of the company's stock, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,862 shares of company stock worth $312,254. Insiders own 0.16% of the company's stock.

Zoetis Stock Up 0.8 %

Shares of NYSE:ZTS traded up $1.28 during midday trading on Friday, reaching $153.58. The company had a trading volume of 3,543,605 shares, compared to its average volume of 2,501,356. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The stock has a market cap of $68.52 billion, a PE ratio of 28.08, a P/E/G ratio of 2.78 and a beta of 0.92. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The business's 50 day moving average price is $158.91 and its 200 day moving average price is $168.32.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.30%. Zoetis's payout ratio is 36.56%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ZTS. Morgan Stanley cut their target price on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. StockNews.com upgraded Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Barclays boosted their price objective on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. Stifel Nicolaus dropped their target price on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Finally, Piper Sandler lifted their price target on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Zoetis currently has an average rating of "Buy" and an average price target of $214.40.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.